202189-78-4

Basic information

• Product Name: BENZENEACETIC ACID, 4-(2-(4-(1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL)-1-PIPERIDINYL)ETHYL-ALPHA, ALPHA-DIMETHYL-
• Synonyms: BENZENEACETIC ACID, 4-(2-(4-(1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL)-1-PIPERIDINYL)ETHYL-ALPHA, ALPHA-DIMETHYL-;2-[4-[2-[4-[1-(2-ethoxyethyl)benzoimidazol-2-yl]-1-piperidyl]ethyl]phenyl]-2-methyl-propanoic acid;4-[2-[4-[1-(2-Ethoxyethyl)-1H-benzimidazol-2-yl]-1-piperidinyl]ethyl]-alpha,alpha-dimethylbenzeneacetic acid;Bilastine;4-[2-[4-[1-(2-Ethoxyethyl)-1H-benziMidazol-2-yl]-1-piperidinyl]ethyl]-α,α-diMethylbenzeneacetic Acid;Benzeneacetic acid,4-[2-[4-[1-(2-ethoxyethyl)-1H-benziMidazol-2-yl]-1-piperidinyl]ethyl]-a,a-diMethyl-;Bilasten;2-[4-[2-[4-[1-(2-ethoxyethyl)benzimidazol-2-yl]piperidin-1-yl]ethyl]phenyl]-2-methylpropanoic acid
• CAS NO: 202189-78-4
• Molecular Formula: C28H37N3O3
• Molecular Weight: 463.61
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Isotope Labelled Compounds
• Mol File: 202189-78-4.mol
• Article Data: 22

Chemical Properties

• Melting Point: 202 °C
• Boiling Point: 639.1°Cat760mmHg
• Flash Point: 340.3°C
• Appearance: /
• Density: 1.16g/cm³
• Vapor Pressure: 3.29E-17mmHg at 25°C
• Refractive Index: 1.594
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.40±0.10(Predicted)
• Water Solubility: Insoluble in water
• CAS DataBase Reference: BENZENEACETIC ACID, 4-(2-(4-(1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL)-1-PIPERIDINYL)ETHYL-ALPHA, ALPHA-DIMETHYL-(CAS DataBase Reference)
• NIST Chemistry Reference: BENZENEACETIC ACID, 4-(2-(4-(1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL)-1-PIPERIDINYL)ETHYL-ALPHA, ALPHA-DIMETHYL-(202189-78-4)
• EPA Substance Registry System: BENZENEACETIC ACID, 4-(2-(4-(1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL)-1-PIPERIDINYL)ETHYL-ALPHA, ALPHA-DIMETHYL-(202189-78-4)

Safety Data

• Hazardous Substances Data: 202189-78-4(Hazardous Substances Data)

Usage

Description

Different sources of media describe the Description of 202189-78-4 differently. You can refer to the following data:
1. Bilastine, a potent and selective histamine H1 receptor antagonist, was approved in Europe in 2010 for the treatment of allergic rhinoconjunctivitis (AR) and urticaria (hives or skin rash). The original synthesis of bilastine involves alkylation of 2-piperidinyl-1H-benzimidazole with a phenethyltosylate, the para position of which is substituted with a dimethyloxazoline moiety serving as a masked carboxylic acid group. Alkylation of the benzimidazole nitrogen with 2-chloroethyl ethyl ether followed by unmasking of the oxazoline moiety with sulfuric acid provided bilastine.In two major clinical trials, bilastine was effective at relieving allergic rhinitis as assessed by measuring the severity of nasal (obstruction, rhinorrhea, itching, sneezing) and nonnasal (ocular itching, tearing, ocular redness, itching of ears, and/or palate) symptoms.
2. Bilastine is a histamine H1 receptor antagonist (IC50 = 180 nM). It is selective for the histamine H1 receptor in a panel of 30 receptors in vitro at 100 μM. Bilastine prevents microvascular extravasation (ED50 = 185 μg/kg, i.v.), bronchospasm (ED50 = 4.6 μg/kg, i.v.), and systemic anaphylaxis (ED50 = 0.2 μg/kg, p.o.) induced by subcutaneous histamine in guinea pigs. It prevents anaphylaxis induced by subcutaneous administration of ovalbumin or dinitrophenylated human albumin (DNP) in sensitized rats when administered at doses of 7.6 and 6.0 mg/kg, respectively. Formulations containing bilastine have been used in the treatment of urticaria and allergic rhinitis.

Originator

FAES FARMA, S.A. (Spain)

Uses

Different sources of media describe the Uses of 202189-78-4 differently. You can refer to the following data:
1. Bilastine is a novel, nonsedating H1-antihistamine developed for symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.
2. Labelled Bilastine. It is a novel, nonsedating H1-antihistamine developed for symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.

Brand name

Bilaxten

Clinical Use

Bilastine is a selective histamine H1 antagonist approved for the treatment of allergic rhinoconjunctivitis and urticaria (hives). This drug, which has proven to be well tolerated in toxicology profiling, 46 was discovered by the Spainsh firm FAES Farma and was approved by the European Union in 2010.

Synthesis

In 2011, Collier and co-workers published a communication describing both the original synthesis of bilastine and an improved route which was amenable to gram-scale production. Collier’s second generation route, shown below, relies upon a convergent approach involving the union of piperidinyl benzimidazole 49 with fully functionalized phenethyl electrophile 48.Coupling the commercially available bromophenyl acetate 44 with cyclic trioxatriborinane 45 under conventional Suzuki conditions furnished styrene 46 in good yield. Alternatively, this vinylation reaction was also performed under Stille conditions with tributyl vinyl stannane in 83% yield. Hydroboration–oxidation of 46 delivered phenethyl alcohol 47 which was then immediately mesylated under basic conditions in toluene to produce adduct 48. This sulfonate was then reacted with piperidine 49 (whose preparation is described in Scheme 7) followed by saponification of the resulting ester 50 to arrive at bilastene (VI) in 26% overall yield from 44. For the preparation of bilastine piperidine 49, commercially available piperidine 51 was first protected as the Boc-carbamate 52 prior to alkylation of the benzimidazole nitrogen atom with 1-chloro-2-ethoxyethane 53, providing compound 54. The Boc group of 54 was removed under acidic conditions to give fragment 49. This sequence produced the desired piperidine component in 86% overall yield from 51.

Drug interactions

Potentially hazardous interactions with other drugs Antivirals: concentration possibly increased by ritonavir. Grapefruit juice: concentration of bilastine reduced.

Metabolism

Not significantly metabolised. Almost 95% of the administered dose was recovered in urine (28.3%) and faeces (66.5%) as unchanged bilastine

InChI:InChI=1/C28H37N3O3/c1-4-34-20-19-31-25-8-6-5-7-24(25)29-26(31)22-14-17-30(18-15-22)16-13-21-9-11-23(12-10-21)28(2,3)27(32)33/h5-12,22H,4,13-20H2,1-3H3,(H,32,33)

Upstream product

• 628-34-2 2-chloroethyl ethyl ether 
• 1181267-32-2 methyl 2-methyl-2-(4-(2-(methylsulfonyloxy)ethyl)phenyl)propanoate 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 32454-35-6 2-(4-bromophenyl)-2-methylpropionic acid 
• 192775-97-6 4-bromo-α,α-dimethyl-α-(4,4-dimethyloxazolin-2-yl) toluene 
• 1181267-30-0 methyl 2-methyl-2-(4-{2-[(4-methylbenzenesulfonyl)oxy]ethyl}phenyl)propanoate 
• 1181267-37-7 2-(4-{2-[4-(1H-benzoimidazol-2-yl)-piperidin-1-yl]-ethyl}phenyl)-2-methyl-propionic acid methyl ester 
• 1394117-23-7 methyl α,α-dimethyl-4-(2-bromoethyl)phenylacetate 
• 202189-76-2 2-{4-[1-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-1-methylethyl]phenyl}ethyl p-toluenesulfonate 
• 1841081-72-8 1-(2-ethoxyethyl)-2-(piperidin-4-yl)-1H-benzo[d]imidazole dihydrochloride 
• 361382-26-5 2-{1-[4-(2-hydroxyethyl)phenyl]-1-methylethyl}-4,5-2H-4,4-dimethyl-oxazole 

Relevant articles and documents

Preparation method of bilastine key intermediate

The invention belongs to the technical field of drug synthesis, and relates to 2 - (4 - (2 - (4 -ethoxyethyl) 1 - benzo [2 -] imidazol - 1H - yl) piperi d-ethyl) phenyl) -2 -methylpropionate (-1 -), and a -2 - complex and II acid are used as a catalyst to condensation the enolate anion with the compound (16 15) to form a target product II Ni Lewis. The invention aims to provide a short synthetic route. The provided route raw material condition is mild, the yield is high, the tedious building quaternary carbon atom method reported in the traditional process is avoided, and the method is suitable for industrial production.

TITLE: PROCESS FOR THE PREPARATION OF BILASTINE

The present invention relates to a process for the preparation of bilastine, a compound of formula I. The present invention relates to p-xylene solvate of bilastine and process for its preparation. The present invention relates to a process for the prepar

Preparation method of bilastine

The invention belongs to the technical field of medicines, and discloses a preparation method of bilastine. 4-piperidinecarboxylic acid and methyl alpha,alpha-dimethyl-4-(2-bromoethyl)phenylacetate which are used as raw materials to prepare methyl alpha,alpha-dimethyl-4-[2-[4-formylpiperidyl]ethyl]phenylacetate, the methyl alpha,alpha-dimethyl-4-[2-[4-formylpiperidyl]ethyl]phenylacetate reacts with o-phenylenediamine to generate methyl alpha,alpha-dimethyl-4-[2-[4-[1H-2-benzimidazolyl]piperidin-1-yl]ethyl]phenylacetate, and chloroethyl ether is added into the obtained product to generate bilastine. The method for synthesizing bilastine by a three-step reaction has the advantages of simple route, easily available raw materials, mild reaction conditions, easiness in control, and suitablenessfor industrial production.